<DOC>
	<DOC>NCT00465192</DOC>
	<brief_summary>This trial was conducted in the United States of America (USA). This trial aimed for a comparison between the effect of two different doses of estradiol on parameters related to efficacy and safety.</brief_summary>
	<brief_title>Efficacy and Safety of 17-Beta Estradiol in Treatment of Atrophic Vaginitis</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Atrophic Vaginitis</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Generally healthy Postmenopausal Hysterectomized or nonhysterectomized Moderate or severe vaginal dryness and soreness Known, suspected, or past history of breast cancer Known, suspected, or past history of hormonedependent tumor Genital bleeding of unknown etiology Acute thrombophlebitis or thromboembolic disorders or a past history of these conditions, associated with previous estrogen use Vaginal infection Use of exogenous corticosteroids or sex hormones within 8 weeks of starting active treatment in study Use of vaginal, oral or vulvar homeopathic preparations within seven days of starting active treatment in study History of treatment with diethylstilbestrol</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>